The Next Era in the Management of Metastatic Colorectal Cancer

To participate in this activity, please:

Greater understanding of the pathology of colorectal cancer has led to the integration of targeted treatment options. But not all targeted treatment options are the same, necessitating thoughtful selection of guideline-recommended therapy in collaboration with the patient. Stacey Cohen, MD, explores the significance of molecular profiling and tumor markers in personalizing immunotherapy for metastatic colorectal cancer. She also delves into the evolving landscape of targeted therapies, discussing the nuances and considerations of different options to optimize patient outcomes.

Course Credit:

0.50 AMA PRA Category 1 CreditsTM

Dates:

Opens: 2024-08-19
Closes: 2025-08-19

Target Audience:

Oncologists, pathologists, oncology nurse practitioners, nurses and physician associates; pharmacists and other healthcare professionals involved in the care of patients diagnosed with metastatic colorectal cancer (mCRC).

This activity is supported by an independent educational grant from Taiho Oncology, Inc.

    Presenting Faculty

  • Stacey A. Cohen, MD  headshot

    Stacey A. Cohen, MD

    Fred Hutchinson Cancer Center
    Associate Professor, Clinical Research Division, Fred Hutch
    Associate Professor, Division of Hematology and Oncology, University of Washington School of Medicine
    Seattle, Washington